The aim of this study was to evaluate the effects of recombinant human adenovirus p53 (rAd-p53; Gendicine) transfection and radiation at various time points following transfection. Cytotoxic effects and p53 protein expression levels were analyzed. rAd-p53 containing the human wild-type p53 gene was introduced into the human lung adenocarcinoma cell line A549, and cells were
Introduction
The wild-type p53 gene (wt-p53), an important tumor suppressor gene, is a key regulatory factor determining cell survival during the cellular stress response to radiation-induced DNA damage. DNA damage responses trigger a series of chemical modifications, including p53 phosphorylation. Activated p53 transcription promotes or inhibits expression of downstream genes, thereby causing cell cycle arrest, DNA repair and tumor cell apoptosis through the regulation of target genes (1, 2) . To date, dysfunction of tumor suppressor genes has been confirmed as the most significant genetic damage in human cancers. Mutations or deletions of p53 occur in 50-70% of non-small cell lung cancers (NSCLCs) and are associated with poor prognosis of lung cancer patients (3, 4) .
A previous study demonstrated that patients with wt-p53 with loss of function were less sensitive to radiotherapy (5) . In vivo and in vitro studies have revealed that wt-p53 transfection in combination with radiotherapy (RT) may increase the sensitivity to low linear energy transfer (LET) radiation (6) (7) (8) ; although mutant p53 may respond well to high LET radiation (9, 10) . Recombinant human adenovirus (Ad) p53 injection (rAd-p53; trade name, Gendicine) is a gene therapy administered intratumorally, which uses type 5 Ad to carry the recombinant human p53 gene. Transfection of Ad is able to introduce the p53 gene into tumor cells to express wt-p53 protein, which may execute its functions in inhibiting cell division and inducing tumor cell apoptosis. Combination therapy of rAd-p53 and radiation has demonstrated good efficacy for the treatment of multiple tumors. It has also been approved as a treatment model for certain head and neck malignancies, including nasopharyngeal carcinoma (11) . Previous studies have revealed that the peak time for wt-p53 expression following Gendicine treatment was 48-72 h after transfection (12) (13) (14) .
Therefore, Gendicine administration twice a week helps to achieve a stable expression platform of wt-p53 proteins. The time of rAd-p53 transfection may overlap with at least one of five-weekly standard RT treatments. However, whether RT may affect the expression of exogenous wt-p53 mediated by Ad, and what the optimal interval between radiation and rAd-p53 treatment is remains unclear.
This study introduced rAd-p53 containing the human wt-p53 gene into the human lung adenocarcinoma cell line A549. RT was applied at various time points following gene transfection in order to evaluate the effect of combination therapy on growth inhibition, cell apoptosis and p53 protein expression. Our aim was to explore the optimal interval time of RT following rAd-p53 transfection, in order to obtain maximum clinical effects.
Materials and methods
Materials. Human lung adenocarcinoma cell line A549 was obtained from the Biological Testing Center of the Cancer Hospital (Chinese Academy of Medical Sciences, Beijing, China), RPMI-1640 culture medium from Gibco (Carlsbad, CA, USA) and 15% fetal bovine serum (FBS) from Hyclone Laboratories Inc., (Logan, UT, USA). The MTT assay was obtained from Sigma (St. Louis, MO, USA), Hoechst 33342/propidium iodide (PI) double-staining kit from GenScript (USA Inc., Piscataway, NJ, USA) and total protein extraction kit from, Nanjing KeyGene Biotechnology Co., Ltd., (Nanjing, China). We obtained the concentrated mouse anti-human p53 monoclonal antibody (1:1000) from Abcam (Cambridge, MA, USA), the ready to use mouse anti-human β-actin monoclonal antibody (1:1000) from Santa Cruz Biotechnology Inc., (Santa Cruz, CA, USA), goat anti-mouse IgG antibody (1:2000) from Beijing Zhongshan Golden Bridge Biotechnology Co., (Beijing, China), human Ad type 5 from Vector BioLabs (Philadelphia, PA, USA) and the recombinant human p53 Ad injection (rAd-p53 injection; trade name, Gendicine; lot number, 20090514; 10 12 viral particles/vial, 2 ml/vial) from Shenzhen Sibiono Gene Technology Co., Ltd. (Shenzhen, China). Plaque assay determined the titer as 1x10 plaque forming unit (PFU)/ vial.
Cell culture. RPMI-1640 culture medium containing 300 µg/ml glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 15% FBS was used. A549 cells were cultured in a 37˚C, 5% CO 2 and 95% O 2 incubator and those at exponential growth phase were selected for further study.
Irradiation. A 6 MeV medical linear accelerator (Siemens Primus, Erlangen, German) was used with a 100 cm source skin distance, 0.5 cm tissue equivalent compensator, 300 cGy/min dose rate and a 4 Gy single dose.
Treatment and grouping. A549 cells at exponential growth phase were cultured in serum-free culture medium for 12 h for cell cycle synchronization, and cultured for a further 24 h. Following cell attachment, 1x10 10 VP/well rAd-p53 injection was added into each group (to infect cells at 1000 PFU/cell), and an equal volume of culture medium was added into the control group. According to the time between rAd-53 transfection and RT, cells were divided into 5 groups: radiation administered immediately following transfection (0 h-RT) group, after 3 h group (3 h-RT), after 6 h group (6 h-RT), after 24 h group (24 h-RT) and after 48 h group (48 h-RT). Cells with rAd-p53 transfection alone (Ad-p53) or with the empty Ad vector transfection (Ad group) were included as the two control groups. Cells of all groups were cultured until 72 h following transfection and were then subjected to 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) assay, flow cytometry and western blot analysis, respectively ( Fig. 1 ).
MTT assay. Following corresponding treatments, cells (2x10 3 / well) were plated in 96-well culture plates and MTT (5 g/l) solution was added into each well and cultured for a further 4 h. The supernatant was discarded from each well and 200 µl dimethyl sulfoxide was added. Following 10 min of agitation, absorbance at 490 nm was measured on a microplate reader and the growth inhibition rate was calculated as follows: Growth inhibition rate = [(A value of the control group -A value of the experimental group) / A value of the control group] x 100%. Results are demonstrated as the mean ± standard deviation (SD).
Flow cytometry. Following corresponding treatments, cells were harvested, adjusted to a cell density of 1x10 6 cells/ml and incubated with Hoechst 33342 dye at 37˚C for 10 min. Cells were centrifuged at 1000 rpm for 5 min at 4˚C and then the supernatant was discarded. Following this, cells were incubated with PI at room temperature for 10 min and the stained cells were immediately analyzed using flow cytometry with UV/488 nm dual excitation. The fluorescence emission of Hoechst 33342 at 460 nm and PI at 640 nm emission were measured.
Western blot analysis. Following corresponding treatments, cells in each group were homogenized at 4˚C and a total protein extraction kit was used for protein extraction. A Coomassie brilliant Blue assay was used to determine the protein concentration to enable us to adjust the extracted protein from each group into the same concentration. The protein was then subjected to 10% denaturing polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride membrane blocked using 50 g/l non-fat milk at room temperature for 1 h. The proteins were then incubated with mouse anti-human p53 monoclonal antibody and concentrated rabbit anti-human β-actin monoclonal antibody, respectively, at 4˚C overnight, followed by horseradish peroxidase-labeled goat anti-mouse IgG antibody at room temperature for 1 h. Protein bands were visualized using a chemiluminescent kit and images were captured. Table I . Effects of rAd-p53 transfection and radiation at various time points in A549 cells. ANOVA, followed by a Student's two-tailed paired t-test for comparison between two groups. P<0.05 was considered to indicate a statistically significant difference.
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Results

Effects of rAd-p53 and radiation at various time points on cell viability.
Our results demonstrated that a combination of rAd-p53 and radiation inhibited A549 cell growth in all groups, and cell viability suppression rates gradually increased from 0 h-RT to 48 h-RT (Table I) 
Effects of rAd-p53 and radiation at various time points on cell apoptosis. Flow cytometry analysis revealed that the percentage of apoptotic cells gradually increased from 0 h-RT
to 48 h-RT (Table I ; Fig. 2 ). The percentage of apoptotic cells in the 6 h-RT, 24 h-RT and 48 h-RT groups were 39.7±5.4, 42.9±6.6 and 52.0±8.9%, respectively, which were statistically significantly higher than that of Ad-p53 (9.2±2.7), 0 h-RT, (30.1±5.4%) and 3 h-RT groups (32.5±4.9). Additionally, no statistically significant differences were detected in the percentage of apoptotic cells among the 6 h-RT, 24 h-RT and 48 h-RT groups (P>0.05).
Effects of rAd-p53 and radiation at various time points on p53 protein expression.
From 0 h-RT to 48 h-RT the p53 protein expression gradually increased (Fig. 3) . The highest p53 protein expression level was detected in the Ad-p53 control group (1.625±0.172), but it was not significantly different from that of the 48 h-RT group (1.590±0.211) (P>0.05). The p53 protein expression level detected in the 6 h-RT group (0.856±0.092) was higher than that in 3 h-RT group (0.643±0.089) (t=2.882; P=0.045), but not significantly different from that of the 24 h-RT group (1.193±0.202) (P>0.05). A higher p53 expression was demonstrated in the Ad control group compared to that of the 0 h-RT (0.509±0.105) and 3 h-RT groups, however there was no statistical difference (P>0.05) (Table I ; Fig. 4 ). The A549 cell viability suppression rates of and percentage of apoptotic cells were positively correlated with p53 protein expression (P=0.012, r=0.87; P=0.015, r=0.85, respectively) ( Fig. 4) . We did not detect the highest peak of p53 protein expression, which may be demonstrated 72 h following transfection.
Discussion
In the absence of DNA damaging factors, p53 protein expression is extremely low in cells, which maintains a wt-p53 protein half-life of 10-20 min through high turnover rate (15) . The C-terminus of the wt-p53 protein is capable of identifying and binding to damaged DNA bases or radiation-induced double-strand DNA breaks. This stabilizes the p53 protein and accumulates in the cells; wt-p53 half-life is extended to 1-2 h (16, 17) . Expression of the wt-p53 protein in tumor cells following Ad transfection may take a certain amount of time.
Studies have demonstrated that p53 protein expression is initiated 3 h following rAd-p53 transfection, with an expression rate of approximately 50% at 12 h and a peak expression at 48-72 h (12) (13) (14) . Based on these results, we selected a 72-h time point to detect all indicators following rAd-p53 infection. The present study revealed that p53 protein expression in the 0 h-RT and 3 h-RT groups was significantly lower than that of the 6 h-RT, 24 h-RT and 48 h-RT groups (P<0.05), suggesting that radiation may affect p53 expression within a short period of time following rAd-p53 administration. This may be due to the decreased transfection power and/or the loss of the bystander killing effect of certain infected tumor cells, which were inhibited or killed by irradiation. Although the 48 h-RT group had the highest level of p53 protein expression, it was not statistically different from that of the 6 h-RT and 24 h-RT groups (P>0.05). This also indicates that radiation greater than 6 h following rAd-53 transfection may have minimal effects on p53 protein expression. Wt-p53 transfection may not only directly inhibit cell division and induce tumor cell apoptosis, but also has a bystander killing effect on tumor cells. Thus, wt-p53 gene therapy may also increase the sensitivity of tumor cells to radiotherapy and increase tumor cell susceptibility to apoptosis (18) . This study demonstrated that in addition to the effect on p53 protein expression, radiation also affects p53-induced tumor cell apoptosis and cytotoxicity. In the 0 h-RT to 48 h-RT groups, the apoptotic rate of A549 cells gradually increased with prolonged rAd-p53 action and interval of radiotherapy. The A549 cell viability suppression rates of the 6 h-RT, 24 h-RT and 48 h-RT groups were not significantly different, but were significantly higher than that of the immediate radiation and 3 h-RT groups. This suggests that a combination of RT within 3 h of rAd-p53 administration is ineffective in causing sufficient synergistic cytotoxic effects on cancer cells. The A549 cell growth inhibition rate was positively correlated with p53 protein expression. The main mechanism of A549 cell growth inhibition in the 0 h-RT and 3 h-RT groups compared with the 6 h-RT, 24 h-RT and 48 h-RT groups may be that radiation reduces wt-p53 protein expression and decreases the radiation-sensitizing effect. Therefore, despite the above reasons leading to the decreased p53 protein expression and suppression of cell viability, a combination of rAd-p53 transfection into lung cancer cells and RT can be selected at 6-48 h following rAd-p53 transfection, rather than immediate to 3 h. Otherwise, radiation may inhibit or damage p53 protein expression carried by the Ad and reduce its ability to directly kill tumor cells or indirectly sensitize them to irradiation.
In conclusion, radiation at various time points is able to affect p53 protein expression and cytotoxic effects of rAd-p53, and administration of RT at 6-48 h following rAd-p53 transfection may maximize the synergistic killing effect of these two treatments on tumor cells. The single high dose of radiation used in in vitro experiments may not accurately reflect the molecular biological changes caused by the conventional fractionated 2 Gy dose used in clinics. However, this study provides a theoretical basis for the reasonable arrangement of rAd-p53 transfection and radiotherapy interval, and further investigation is required.
